NUVB Stock Analysis: Nuvation Bio | NYSE
Biotechnology | NYSE, USA | Market Cap: 2.204m USD | 12M Return: 166.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 37.5M
Qual. Beats: 0
Qual. Beats: 9
Warnings
Tailwinds
Seasonality 5.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nuvation Bio Inc. (NYSE: NUVB) is a U.S.-based, clinical-stage biopharmaceutical company founded in 2018 and headquartered in New York, focused on developing oncology product candidates. Its lead asset, IBTROZI (taletrectinib), is a ROS1 inhibitor for patients with ROS1-positive non-small cell lung cancer (NSCLC). The company is also advancing Safusidenib, a mutant IDH1 inhibitor currently in Phase 3 trials as a maintenance therapy for high-risk IDH1-mutant astrocytoma. Nuvation went public in August 2020 and operates as a small-cap biotechnology company within the Health Care sector.
As a clinical-stage biotech, Nuvation does not yet generate meaningful product revenue and relies on capital markets and potential partnerships to fund its research and development pipeline. The companys focus on genetically defined oncology targets, such as ROS1 and IDH1 mutations, reflects a broader industry shift toward precision medicine and biomarker-driven cancer therapies.
- IBTROZI sales accelerate following ROS1+ NSCLC commercial launch
- Safusidenib Phase 3 data for IDH1 astrocytoma looms as catalyst
- Repotrectinib approval intensifies ROS1 inhibitor competition for IBTROZI
| Net Income: -146.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 125.6 > 1.0 |
| NWC/Revenue: 357.9% < 20% (prev 3.86k%; Δ -3.50k% < -1%) |
| CFO/TA -0.21 > 3% & CFO -125.7m > Net Income -146.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (377.5m) vs 12m ago 11.49% < -2% |
| Gross Margin: 91.64% > 18% (prev 16.29%; Δ 75.35% > 0.5%) |
| Asset Turnover: 25.94% > 50% (prev 2.22%; Δ 23.72% > 0%) |
| Interest Coverage Ratio: -6.48 > 6 (EBIT TTM -131.7m / Interest Expense TTM 20.3m) |
| A: 0.84 (Total Current Assets 591.5m - Total Current Liabilities 79.5m) / Total Assets 610.2m |
| B: -1.82 (Retained Earnings -1.11b / Total Assets 610.2m) |
| C: -0.24 (EBIT TTM -131.7m / Avg Total Assets 551.4m) |
| D: 1.10 (Book Value of Equity 319.6m / Total Liabilities 290.7m) |
| Altman-Z'' = -0.88 = CCC |
| DSRI: 0.36 (Receivables 26.0m/5.46m, Revenue 143.0m/11.0m) |
| GMI: 0.18 (GM 16.29% / 91.64%) |
| AQI: 1.07 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 13.06 (Revenue 143.0m / 11.0m) |
| TATA: -0.03 (NI -146.0m - CFO -125.7m) / TA 610.2m) |
| Beneish M = 4.39 (Cap -4..+1) = D |
As of August 04, 2026, the stock is trading at USD 6.16 with a total of 4,714,385 shares traded. Over the past week, the price has changed by -7.51%, over one month by +10.00%, over three months by +39.68% and over the past year by +166.67%.
Current recommended Stop Loss: 5.60 (which is 9.1% or 1.4 ATR below the current price).
Nuvation Bio has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy NUVB.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.8 | 107.5% |
P/S = 15.4085
P/B = 7.3004
Revenue TTM = 143.0m USD
EBIT TTM = -131.7m USD
EBITDA TTM = -129.7m USD
Long Term Debt = 47.3m USD (from longTermDebt, last quarter)
Short Term Debt = 7.63m USD (from shortTermDebt, last quarter)
Debt = 59.0m USD (corrected: LT Debt 47.3m + ST Debt 7.63m) + Leases 4.04m
Net Debt = -270.4m USD (calculated: Debt 59.0m - CCE 329.4m)
Enterprise Value = 1.93b USD (2.20b + Debt 59.0m - CCE 329.4m)
Interest Coverage Ratio = -6.48 (Ebit TTM -131.7m / Interest Expense TTM 20.3m)
EV/FCF = 32.39x (Enterprise Value 1.93b / FCF TTM 59.7m)
FCF Yield = 3.09% (FCF TTM 59.7m / Enterprise Value 1.93b)
FCF Margin = 41.74% (FCF TTM 59.7m / Revenue TTM 143.0m)
Net Margin = -102.1% (Net Income TTM -146.0m / Revenue TTM 143.0m)
Gross Margin = 91.64% ((Revenue TTM 143.0m - Cost of Revenue TTM 12.0m) / Revenue TTM)
Gross Margin QoQ = 93.25% (prev none%)
Tobins Q-Ratio = 3.17 (Enterprise Value 1.93b / Total Assets 610.2m)
Interest Expense / Debt = 34.47% (Interest Expense 20.3m / Debt 59.0m)
Taxrate = 0.0% (0.0 / 5.40m)
NOPAT = -131.7m (EBIT -131.7m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 5.80 (Total Current Assets 591.5m / Total Current Liabilities 102.0m)
Debt / Equity = 0.18 (Debt 59.0m / totalStockholderEquity, last quarter 319.6m)
Debt / EBITDA = 2.08 (negative EBITDA) (Net Debt -270.4m / EBITDA -129.7m)
Debt / FCF = -4.53 (Net Debt -270.4m / FCF TTM 59.7m)
Total Stockholder Equity = 331.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.48% (Net Income -146.0m / Total Assets 610.2m)
RoE = -44.10% (Net Income TTM -146.0m / Total Stockholder Equity 331.0m)
RoCE = -34.81% (EBIT -131.7m / Capital Employed (Equity 331.0m + L.T.Debt 47.3m))
RoIC = -24.79% (negative operating profit) (NOPAT -131.7m / Invested Capital 531.2m)
WACC = 8.97% (E(2.20b)/V(2.26b) * Re(8.29%) + D(59.0m)/V(2.26b) * Rd(34.47%) * (1-Tc(0.0)))
Discount Rate = 8.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.08 | Cagr: 27.45%
[DCF] Terminal Value 73.28% ; FCFF base≈59.7m ; Y1≈60.0m ; Y5≈63.5m
[DCF] Fair Price = 3.35 (EV 893.2m - Net Debt -270.4m = Equity 1.16b / Shares 347.2m; r=8.97% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.08 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 4.0 | # QB: 9
EPS current Quarter (2026-06-30): EPS=-0.12 | Chg30d=-9.09% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.11 | Chg30d=-22.22% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.28 | Chg30d=-27.27% | Revisions=-25% | GrowthEPS=+43.3% | GrowthRev=+222.6%
EPS next Year (2027-12-31): EPS=-0.06 | Chg30d=+58.62% | Revisions=-25% | GrowthEPS=+78.6% | GrowthRev=+42.9%